Incyte Co. (NASDAQ:INCY) EVP Dashyant Dhanak sold 396 shares of the business’s stock in a transaction that occurred on Thursday, April 1st. The shares were sold at an average price of $81.57, for a total value of $32,301.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ INCY opened at $81.38 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.56 and a quick ratio of 3.53. The stock’s fifty day moving average price is $80.22 and its two-hundred day moving average price is $85.97. Incyte Co. has a one year low of $75.52 and a one year high of $110.36. The firm has a market cap of $17.89 billion, a price-to-earnings ratio of -51.83, a P/E/G ratio of 0.98 and a beta of 0.96.
Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Monday, February 8th. The biopharmaceutical company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.30. The firm had revenue of $788.50 million for the quarter, compared to analyst estimates of $654.08 million. Incyte had a negative return on equity of 13.66% and a negative net margin of 13.62%. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.65 EPS. On average, equities analysts anticipate that Incyte Co. will post -1.45 earnings per share for the current fiscal year.
Several equities research analysts have commented on the company. SVB Leerink cut Incyte from a “market perform” rating to an “underperform” rating and cut their target price for the company from $89.00 to $70.00 in a research note on Wednesday, February 10th. Guggenheim raised Incyte from a “neutral” rating to a “buy” rating in a research report on Monday, January 4th. TheStreet lowered Incyte from a “b-” rating to a “c” rating in a research report on Monday, March 15th. Morgan Stanley lowered their price target on Incyte from $93.00 to $86.00 and set an “equal weight” rating on the stock in a research report on Monday. Finally, Truist began coverage on Incyte in a research report on Thursday, January 7th. They set a “buy” rating and a $120.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $101.88.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Featured Story: What is a Market Correction?
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.